171 related articles for article (PubMed ID: 38425450)
1. Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.
Su J; Harati Taji Z; Kosinska AD; Ates Oz E; Xie Z; Bielytskyi P; Shein M; Hagen P; Esmaeili S; Steiger K; Protzer U; Schütz AK
JHEP Rep; 2024 Apr; 6(4):100997. PubMed ID: 38425450
[TBL] [Abstract][Full Text] [Related]
2. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
[TBL] [Abstract][Full Text] [Related]
3. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.
Sacherl J; Kosinska AD; Kemter K; Kächele M; Laumen SC; Kerth HA; Öz EA; Wolff LS; Su J; Essbauer S; Sutter G; Scholz M; Singethan K; Altrichter J; Protzer U
JHEP Rep; 2023 Feb; 5(2):100603. PubMed ID: 36714793
[TBL] [Abstract][Full Text] [Related]
4. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection.
Kosinska AD; Festag J; Mück-Häusl M; Festag MM; Asen T; Protzer U
Vaccines (Basel); 2021 Jul; 9(8):. PubMed ID: 34451966
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
7. Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting.
Chuai X; Chen H; Wang W; Deng Y; Wen B; Ruan L; Tan W
PLoS One; 2013; 8(1):e54126. PubMed ID: 23335993
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
Schödel F; Peterson D; Milich D
Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
[TBL] [Abstract][Full Text] [Related]
9. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
[TBL] [Abstract][Full Text] [Related]
10. HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production.
Chuai X; Xie B; Deng Y; Zhao Y; Wang W; Gao Z; Wang W; Qiu X; Tan W
Antiviral Res; 2019 Jan; 161():20-27. PubMed ID: 30423362
[TBL] [Abstract][Full Text] [Related]
11. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
[TBL] [Abstract][Full Text] [Related]
13. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
[TBL] [Abstract][Full Text] [Related]
14. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine.
Makidon PE; Bielinska AU; Nigavekar SS; Janczak KW; Knowlton J; Scott AJ; Mank N; Cao Z; Rathinavelu S; Beer MR; Wilkinson JE; Blanco LP; Landers JJ; Baker JR
PLoS One; 2008 Aug; 3(8):e2954. PubMed ID: 18698426
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
Zhang Y; Bourgine M; Wan Y; Song J; Li Z; Yu Y; Jiang W; Zhou M; Guo C; Santucci D; Liang X; Brechot C; Zhang W; Charneau P; Wu H; Qiu C
J Hepatol; 2024 Jan; 80(1):31-40. PubMed ID: 37827470
[TBL] [Abstract][Full Text] [Related]
17. Potentiating humoral and cellular immunity using a novel hybrid polymer-lipid nanoparticle adjuvant for HBsAg-VLP vaccine.
Liu X; Min Q; Song H; Yue A; Li Q; Zhou Q; Han W
J Nanobiotechnology; 2023 Nov; 21(1):441. PubMed ID: 37993870
[TBL] [Abstract][Full Text] [Related]
18. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
19. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
20. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo.
Furukawa S; Akbar SM; Hasebe A; Horiike N; Onji M
Immunobiology; 2004; 209(7):551-7. PubMed ID: 15568619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
